Audit: QRS - High-Intensity Interval Training for Health & Longevity

Audit conducted on 31/08/2026 05:20 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to Therapeutic Protocol, time cells to Practical Considerations / Therapeutic Protocol / Expected Benefits, benefit and risk tiers to the ER tier headings verbatim, all 10 markers to the ER monitoring table, all 5 qualitative items to the ER qualitative list.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	No ER source section is empty and no cautious-phrasing construct is carried into the QRS; hedged ER items (e.g. “More than 3 weekly sessions has not been shown to add benefit”) retain the ER’s own hedge in action_3_sub.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Interaction severity words (“Caution”, “Monitor”, “Generally compatible”) are carried over unchanged from the ER; contraindication thresholds and windows are unchanged.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from the ER “Populations who should avoid” list; Key Interactions only from the ER interaction bullets; no Benefit-Modifying Factors or Risk-Modifying Factors content is surfaced in either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, expert names or study citations appear anywhere in the QRS. All named drugs (metoprolol, bisoprolol, carvedilol, glipizide, glimepiride, empagliflozin, dapagliflozin, atorvastatin, rosuvastatin, ibuprofen, naproxen, synephrine, yohimbine) appear in the ER for the same interaction bullet.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears in the QRS; the ER’s attributions (Wisløff, Gibala, McMaster, NTNU) were dropped rather than added to.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, declarative, evidence-first register throughout, mirroring the ER; British spellings (“programme”) carried through consistently from the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Protocol and Time-to-effect panels give concrete, achievable parameters; the at-a-glance names the payoff and the failure mode without alarmism.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as noun phrases and observed facts; no imperatives are directed at a reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	The gates state conditions and interaction ratings as facts carried from the ER, not as instructions issued by the sheet.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “advised”, “should” or equivalent appears in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun (“you”, “your”) occurs anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to the decision gates and monitoring table where precision is load-bearing; the at-a-glance and protocol cells use plain wording (“brief bouts of hard effort”, “easy recovery”, “active recovery”).
2.8	Information is presented in a concise and very compact manner	🟢	Every benefit, risk, contraindication and interaction is a short phrase; no ER prose, mechanism, effect size or citation is carried into any item.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address anywhere in the sheet.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Optimal-range monitoring targets (HbA1c 4.8–5.3%, fasting insulin 2–5 µIU/mL, ApoB below 80 mg/dL, hs-CRP below 1.0 mg/L) are pitched to an optimizing audience, not conventional lab flags.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A 2–3× weekly near-maximal protocol plus a 10-marker laboratory panel and continuous wearable tracking assumes exactly this willingness.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No concessions to minimal effort; the sheet states the 85–95% maximal-heart-rate band and the sprint format without softening.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance names abandonment as the likeliest failure and injury as common — the two signals that matter most to a motivated self-directed trainee — and the Risks card leads with musculoskeletal injury and tolerability.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header topic; the string “anti-aging” appears nowhere in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Gates, Risks and Monitoring use formal terms throughout (“myocardial infarction”, “exertional rhabdomyolysis”, “left ventricular ejection fraction”, “apolipoprotein B”). The plainer register of the at-a-glance is required by item 7.4 and mirrors the ER Conclusion verbatim in substance.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings verified byte-identical to [qrs_template]: “Protocol” (line 443), “Time to effect” (483), “Benefits” (528), “Risk & Side Effects” (596), “Monitoring” (626), “Qualitative Assessment” (758), “Contraindications” (560), “Key Interactions” (574), all four tier labels in both Benefits and Risks, and “Marker”/”Target”/”Why” (630–632).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	A name-set diff against [qrs_template] returns an empty “in template, not in QRS” set. The repeatable template placeholders marker_#_* and qualitative_item_# are correctly instantiated as marker_1..10_* and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff of the QRS against [qrs_template] with variable regions masked shows changes only inside data-qrs-var spans, the metadata block and the <title>. The non-variable spans (website="evidence_review", website="audit", website="full_review"), all CSS, the footer disclaimer and the document skeleton are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty — all four benefit tiers, all four risk tiers, the contraindication list, the interaction list, the monitoring table and the qualitative list are populated in the ER.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“Norwegian 4x4 protocol”, “Low-volume sprint format”, “Frequency”) and interaction labels (“Beta-blockers (metoprolol, bisoprolol, carvedilol)”, “Stimulant pre-workout supplements (high-dose caffeine, synephrine, yohimbine)”, “High-dose vitamin C and vitamin E”, “Beetroot nitrate and other blood-pressure-lowering supplements”, “Berberine and other glucose-lowering supplements”, “Other interventions — concurrent resistance training”) are carried over verbatim. Where a parenthetical mixed a lay gloss with the example drug list, the drug list is preserved and only the gloss trimmed — the trimming expressly authorised by item 9.5.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No label is abbreviated: “Nonsteroidal anti-inflammatory drugs” is not reduced to “NSAIDs”, and marker names keep the ER’s full term with only the ER’s own parenthetical acronym dropped (“Maximal oxygen uptake”, “High-sensitivity C-reactive protein”, “Apolipoprotein B”, “Creatine kinase”, “Estimated glomerular filtration rate”).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	A scan for 🟩 / 🟥 / 🟨 / ⚠ returns zero matches; the ER’s “⚠️ Conflicted” markers on three benefit and risk items were correctly dropped. Tiering is carried by the .benefits / .risks CSS palettes and the bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to short phrases rather than ER prose: benefit and risk tiers are bare noun phrases with all magnitudes, mechanisms and citations stripped; contraindications and interactions carry only the key fact plus the mandated qualifiers; monitoring targets and “Why” cells are reduced to a single clause each from multi-clause ER table cells. The residual length is driven entirely by the completeness that items 8.2, 9.2, 12.2, 13.2, 14.2 and 15.2 mandate, not by under-condensation of any section.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: a single HTML comment opening immediately after <!doctype html> on line 1 and closing before the template’s own <!-- QRS (Quick Reference Sheet) — blank template --> comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3 and closing --- on line 13; the preceding text “QRS — Metadata (invisible, parsed by audit tooling)” sits before the opening delimiter as permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block sits entirely inside an HTML comment and no metadata value is echoed by any element in <body> other than values independently required by items 6.3 and 6.4.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Verified with cat -A: no leading or trailing whitespace on any of the nine value lines. Only duration: "00:03" is quoted, correctly, because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: high_intensity_interval_training_2026-0831-0328_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the head of [qrs_prompt].
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0831-0504, conforming to the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — a single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” = nickname + version number, with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: high_intensity_interval_training_2026-0831-0328_Opus_QRS.html, matching the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys including the appended git_user: evipedia-5 and git_issue: 5644; both unquoted and untrimmed of nothing.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: High-Intensity Interval Training for Health & Longevity - Quick Reference Sheet, matching the ER canonical_topic with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: High-Intensity Interval Training for Health & Longevity, identical to the ER canonical_topic with the ampersand encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/31/2026, the correct MM/DD/YYYY rendering of qrs_creation_date: 2026-0831-0504.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template’s fixed subline; the ER’s alternate_names line (HIIT, SIT, Norwegian 4x4, …) is correctly absent, as are any badge, version stamp, audit date or variant marker.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three ER Conclusion paragraphs into one block: the fitness/survival core, the secondary cardiometabolic and mental benefits with the time advantage, and the two dominant failure modes.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“peak ability to take in and use oxygen” and “among the strongest markers of how long people live” from Conclusion ¶1; “Lower blood pressure, better blood sugar handling, less abdominal fat, better mood and thinking” from Conclusion ¶1; “in far less time than gentler exercise” from “the real advantage is that they arrive in a fraction of the time”; “Injuries are common” from “Strains and joint injuries are common”; “stopping is the likeliest failure” from “The most likely failure is simply stopping”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “VO₂max” is rendered as “peak ability to take in and use oxygen”, and every remaining term (“hard effort”, “recovery”, “blood pressure”, “blood sugar handling”, “abdominal fat”, “mood”, “thinking”) is everyday vocabulary.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect size, confidence interval, hazard ratio or standardized mean difference appears; the ER’s magnitudes are all omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items map one-to-one onto the “Populations who should avoid High-Intensity Interval Training” list inside the ER Key Interactions & Contraindications section (ER lines 349–355).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER contraindications are present and none is invented: recent myocardial infarction, unstable angina / NYHA IV heart failure, uncontrolled arrhythmia / LVEF below 20%, severe aortic stenosis / obstructive hypertrophic cardiomyopathy, resting BP above 200/110 mmHg, diabetic retinopathy, and acute febrile illness / recent myocarditis.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 563–569: seven discrete <li>…</li> elements inside the stop_items span, within the gate’s <ul>.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale is stripped throughout: the ER’s “, where maximal straining raises the risk of bleeding into the eye” is gone from the retinopathy item, and “has been completed” from the myocardial-infarction item. No dash-introduced trailing clause survives; the only en-dash present is inside the “3–6 months” numeric range.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every decision-relevant qualifier survives: time windows “within the previous 4 weeks” and “within the previous 3–6 months”; severity classes “New York Heart Association Class IV” and “Proliferative or severe non-proliferative”; thresholds “below 20%”, “under 1.0 cm²” and “above 200/110 mmHg”; and the staging “obstructive” on hypertrophic cardiomyopathy. Only pure lay glosses (“a narrowed main heart valve”, “the share of blood the heart ejects per beat”) were trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses; its parentheses contain only lay glosses and one area threshold.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state HTML comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one onto the ten bullets of the ER Key Interactions & Contraindications section (ER lines 327–345), in the ER’s own order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten interaction bullets are present, and none of the seven contraindication populations is duplicated here.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 577–586: ten discrete <li>…</li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to the bold label plus the single rating word (“Caution”, “Monitor”, “Generally compatible”); every ER mechanism and mitigation clause is stripped (e.g. the beta-blocker item drops “They blunt maximal heart rate…”, the SGLT2 item drops the euglycaemic-ketoacidosis explanation). The only em-dash present sits inside the ER’s own bold label “Other interventions — concurrent resistance training” and is therefore not a trailing clause.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every example drug list survives: (metoprolol, bisoprolol, carvedilol), (glipizide, glimepiride), (empagliflozin, dapagliflozin), (atorvastatin, rosuvastatin), (ibuprofen, naproxen), (high-dose caffeine, synephrine, yohimbine). Only the co-located lay definitions (“drugs that push blood sugar down”, “diabetes drugs that make the kidneys flush out glucose”, “cholesterol-lowering drugs”, “over-the-counter painkillers”) were trimmed — the shortening this item expressly permits.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals contain only lay glosses and comma-separated drug examples; no ranking notation is used.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten such interactions, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state HTML comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets derive from the ER Therapeutic Protocol section (ER lines 377–383).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two named executable formats (Norwegian 4x4, low-volume sprint) plus weekly frequency are the three parameters a reader must fix to execute; the remaining ER bullets (best time of day, single vs. split, genetic influences, sex, age, baseline biomarkers, pre-existing conditions) are refinements rather than the core prescription.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section names twelve bullets, well above three, so all three action sets are used and no set is left unfilled.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content: “4 × 4 min at 85–95% of maximal heart rate” / “3 minutes of active recovery, after a 10-minute warm-up. The most-studied clinical format.”; “3 × 20-second all-out sprints” / “Inside a 10-minute session, 3 times weekly. Lower time cost, higher perceived strain, smaller aerobic gain.”; “2–3 sessions weekly” / “The dose used in almost all positive trials. More than 3 weekly sessions has not been shown to add benefit.” No placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Maximal oxygen uptake (2–4 weeks), blood pressure and insulin sensitivity (4–8 weeks) and body composition (8–12 weeks) are exactly the three onset windows the ER’s Practical Considerations “Time to effect” bullet names.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordering follows the ER Expected Benefits High tier in sequence: increased cardiorespiratory fitness (first and largest), lower resting blood pressure with improved glycemic control, then reduced total and central body fat.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect windows, so all three sets are used and none is left unfilled.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content: the sub-lines trace to “Programmes shorter than 4 weeks produce significantly smaller fitness gains” (Practical Considerations), “Improved insulin sensitivity after one session lasts roughly 24–72 hours” (Therapeutic Protocol, “Persistence of the effect”) and “Fat loss comes largely from the energy cost of the session plus elevated post-exercise metabolism” (Expected Benefits).
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information, so the section is correctly retained in the Protocol panel.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All thirteen items map one-to-one onto the ER Expected Benefits sub-headings, tier for tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (lines 530, 537, 542, 548), each matching the corresponding ER tier: six High, two Medium, three Low, two Speculative.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading as a noun phrase; every ER magnitude line (+5.98 mL/kg/min, −3.2 mmHg, HR 0.63, PSQI −0.90, etc.), mechanism paragraph and study link is stripped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needed to be hidden and no empty-state phrasing was called for.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All nine items map one-to-one onto the ER Potential Risks & Side Effects sub-headings, tier for tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 598, 604, 609, 616), each matching the corresponding ER tier: three High, one Medium, four Low, one Speculative.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER sub-heading as a noun phrase; the ER’s injury rates (4.3 per 1,000 hours), event rates (one arrest per 23,182 hours), dropout figures (17.6%) and odds ratio (2.46) are all stripped, as are the “⚠️ Conflicted” markers.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the four risk spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed to be hidden and no empty-state phrasing was called for.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All ten rows and the cadence line derive from the ER Monitoring Protocol & Defining Success section (ER lines 460–473).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarker-table rows are present in order: maximal oxygen uptake, resting heart rate, heart rate variability, blood pressure, HbA1c, fasting insulin, high-sensitivity C-reactive protein, apolipoprotein B, creatine kinase, estimated glomerular filtration rate. Targets are carried faithfully (50–65 bpm, 110–120/70–80 mmHg, 4.8–5.3%, 2–5 µIU/mL, below 1.0 mg/L, below 80 mg/dL, 40–200 U/L, above 90 mL/min/1.73 m²).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 750–752 reproduce the ER’s cadence accurately: baseline before starting; fitness test and blood pressure at 12 weeks then every 6–12 months; metabolic panel and inflammation marker at 3 months then annually; resting heart rate and heart rate variability tracked continuously by wearable.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items derive from the “Qualitative markers worth tracking alongside the laboratory set” list in the ER Monitoring Protocol & Defining Success section (ER lines 477–481).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present in order: perceived effort at a fixed workload, recovery time after a hard session, sleep quality and waking restored, daytime energy and mood stability, cognitive clarity and working memory. The ER’s trailing rationale clauses (“which the sleep data suggest…”, “since falling motivation is an early overreaching signal”) are correctly stripped.

Issues 31/08/2026 05:20

Pass rate 100.00%. No issues found.

Issues 31/08/2026 05:12

1. 4.5 — Monitoring and Qualitative not condensed: The ten marker_#_why cells, most marker_#_target cells (QRS lines 638–744) and all five qualitative_item_# values (QRS lines 762–779) are copied word-for-word from the ER rather than condensed to the per-section budget, forcing the Monitoring table to roughly 21 wrapped lines and the sheet as a whole to roughly twice the one-A4-page print budget.

Fixes 31/08/2026 05:12

1. 4.5 — Monitoring “Why” cells condensed: All ten marker_#_why values were shortened from the ER’s verbatim wording to single-line phrases (e.g. “Counts the artery-clogging particles; the lipid measure least distorted by exercise-induced shifts” → “The lipid measure least distorted by exercise”), cutting the table from roughly 21 to roughly 12 wrapped lines.
2. 4.5 — Monitoring “Target” cells condensed: marker_3_target, marker_8_target and marker_9_target were tightened while keeping every threshold (e.g. “Below 80 mg/dL, or below 60 mg/dL at high cardiovascular risk” → “Below 80 mg/dL; below 60 at high cardiovascular risk”); marker_3_target also regained the ER’s “No universal target” caveat.
3. 4.5 — Qualitative items condensed: qualitative_item_1, _3 and _4 were trimmed to their operative marker, dropping the ER’s trailing rationale clauses, reducing the card from roughly 8 to 5 wrapped lines.
4. 4.5 — Cadence and protocol sub-text tightened: monitoring_cadence and time_3_sub were reworded more compactly without changing content, each saving a wrapped line.
5. 4.5 — Contraindication item shortened: The aortic stenosis bullet was condensed to “Severe symptomatic aortic stenosis (under 1.0 cm²), or obstructive hypertrophic cardiomyopathy”, preserving the severity class and the 1.0 cm² threshold.